Peptide guide: eight compound pages and the questions they answer
- AOD-9604: human evidence
- BPC-157: human reports
- CJC-1295: human studies
- Counterfeit GLP-1: product tests and cases
- Ipamorelin: human studies
- Melanotan II: human findings
- Retatrutide: trial results
- TB-500: fragment evidence
Links and child summaries checked 24 August 2026. Each linked guide carries the date its own claims were checked.
This peptide guide is an index to eight full compound pages. It does not rank compounds or tell a reader which one to choose. Where a human finding exists, the guide keeps it beside the named study, population, limits, and funder. Product identity and vial tests remain separate from clinical results. The index shows which page contains each question.
The eight links cover different kinds of evidence question. Their order is not a preferred order.
Eight peptide guides and what each one covers
This list of peptides is limited to compounds with a full written guide on this site. Register entries cover more names, but they serve a different task. The guides below bring together research results, limits, funding, trial records, agency material, and direct product data where those sources exist.
The different types of peptides here do not form one evidence tier. Some pages lead with human results. Some lead with a direct absence of published human data. One page concerns products sold as a medicine rather than one research compound. The same page structure does not turn those different records into a ranking.
What human evidence exists for AOD-9604?
The AOD-9604 guide starts with the published human pain result and its primary endpoint. It keeps that result separate from the earlier safety paper and its missing weight-loss results. Positive animal findings remain in their own section. The page also covers registered trials, direct product analysis, and agency records.
This guide separates results from people and animals. It states the human weight-loss data gap directly. It also keeps the oral study molecule and the vial question in separate frames. No animal finding is presented as a human result.
What do the BPC-157 human reports show?
The BPC-157 register article brings together the published human reports and the limits of each one. It states the absence of a controlled human tissue-healing result. Registered trials appear apart from completed reports. The page also includes direct vial data, agency records, and the distinction from TB-500.
Readers searching for peptides for healing can use the page to see which outcomes were actually measured in people. The page does not convert symptom reports into proof of tendon or muscle repair. Funder statements and the lack of control groups stay beside the reports they limit.
What did CJC-1295 studies measure?
The CJC-1295 guide covers the human hormone studies and identifies the long-acting molecule used in them. It states which outcomes those studies did not measure. Trial-recorded adverse events remain with the human data. A forum account, vial tests, and agency records appear in separate sections.
The page also explains the DAC distinction because names used in discussion do not always point to the same molecule. It does not infer muscle gain, recovery, sleep, or fat loss from a hormone measurement. Each limit stays beside the study that created it.
What did tests and case reports find in products sold as semaglutide?
The counterfeit GLP-1 guide separates the effects of genuine medicines from data about products sold under their names. It covers direct vial purchases, confirmed insulin substitution, published clinical cases, and European safety reports. The page also explains what visual checks and spontaneous-report counts cannot prove.
This guide is about product identity and reported cases, not a ranking of sellers. A laboratory-confirmed case stays separate from a suspected report. Two papers about one purchase dataset are treated as one test series rather than two independent experiments.
What have ipamorelin studies reported?
The ipamorelin guide starts with the published human hormone data. It keeps those measurements separate from outcomes the studies did not test. The page also covers the larger completed trial with no posted result, trial-recorded effects, a user account, product tests, and agency records.
The guide does not turn a hormone response into proof of muscle gain or recovery. It names the funding information available in each record. It also keeps the combined user account with CJC-1295 apart from controlled data about ipamorelin alone.
What human findings exist for melanotan II?
The melanotan II guide leads with the published human tanning result. It keeps the study's recorded effects and limits in the same section. A recruiting trial, one user account, the nasal-spray data gap, vial tests, and agency records appear as separate questions.
The page distinguishes the studied molecule from the form claimed on a product label. It does not use the tanning result to establish the identity of a purchased vial. The guide also states when a search found no usable human data for a different product form.
What did retatrutide trials measure?
The retatrutide guide covers later-phase and earlier human weight-loss results. Trial funders, populations, differing source counts, reported adverse events, and effect intervals stay with those findings. The page covers vial tests and current availability records apart from the trials.
The guide does not compare trials run apart as if they were one head-to-head experiment. It states where a sponsor report and a registry use different counts. It also keeps product availability apart from what the trials measured.
What evidence exists for the exact TB-500 fragment?
The TB-500 guide opens with the absence of a published human result for the exact fragment. It then covers the direct animal and laboratory findings without relabelling them as human data. Product tests, agency records, and the distinction from the parent peptide each have their own section.
The page answers questions about TB-500 itself. Human studies of the parent molecule remain clearly labelled as data about that parent. A missing human result is stated directly rather than turned into a verdict on future research.
Having a full guide does not mean that every source type exists for every compound. It means the page states what was found and what was not found. A human study remains different from an animal study. A registered trial with no public result remains different from a published result. A vial test remains different from both.
The guides also keep funding beside the research. Where an opened paper names a funder, the page names it beside the finding. Where the accessible record gives no funding statement, the page says that instead. The index does not turn either form into a score.
Open the human-study section when the question is what happened in a named group. The population and measured outcome stay on that page. Open the trial-record section when the question is what work was registered or remains without a result. A registry entry is not presented as proof that a compound worked.
Product data has its own place. A test can address the identity, amount, purity, or another measured field in a sample. It cannot replace the clinical paper for a human outcome. A clinical paper cannot establish what was in a vial bought elsewhere. Each guide preserves that boundary where product data exists.
Forum accounts remain another kind of record. The relevant guides label them as self-reported and self-selected. They link to the complete thread when it could be opened. An individual account remains an individual account.
The index therefore routes by question. It does not award one compound a higher position because its page contains more sections. An explicit absence can answer the page's main question. A positive result can also remain clear without being turned into a recommendation.
This peptides list works by question, not by a score. Human findings stay with human studies. Animal findings stay with animal work. Forum accounts remain self-reported and self-selected. Vial data answers what a tested sample contained, not what a compound did in a trial.
Different types of peptides can therefore sit in the same index without being treated as interchangeable. Open the guide whose question matches the source material you want to inspect. The page itself will show the strongest measured result first, then the limits and other material that belong with it.